Does first-line therapy with drug combinations improve survival in adults with pulmonary arterial hypertension?
First-line combination therapy targeting multiple biological pathways is associated with improved survival in patients with pulmonary arterial hypertension.
Pulmonary arterial hypertension affects an estimated 10.6 per 1 million adults in the US and, without treatment, typically progresses to right heart failure and death. First-line therapy with drug combinations that target multiple biological pathways are associated with improved survival.
Ruopp et al. (Tue,) studied this question.